×
About 1,330 results

ALLMedicine™ Infantile Hemangioma Center

Research & Reviews  443 results

Skin sequelae in patients with infantile hemangioma: a systematic review.
https://doi.org/10.1007/s00431-022-04688-1
European Journal of Pediatrics; Li W, Kang J et. al.

Nov 27th, 2022 - Infantile hemangioma (IH) is the most common vascular tumor in infancy. Although IHs can regress spontaneously, some problematic IHs still need treatment. However, either treated or untreated IHs may leave skin sequelae which can cause permanent d...

Shikonin reverses PKM2-mediated propranolol resistance in infantile hemangioma through ...
https://doi.org/10.1111/cas.15649
Cancer Science; Yang E, Wang X et. al.

Nov 13th, 2022 - Infantile hemangioma (IH) is the most common benign tumor in infancy. Propranolol, a nonselective β-adrenergic receptor blocker, is now the first-line therapy for IH. Recently, low sensitivity to propranolol therapy has become one major reason for...

Bleomycin-triamcinolone sclerotherapy in the management of propranolol resistant infant...
https://doi.org/10.1016/j.jormas.2022.10.012
Journal of Stomatology, Oral and Maxillofacial Surgery; Tiwari P, Bera RN et. al.

Oct 20th, 2022 - Propranolol has emerged as a first line agent in the management of hemangiomas. With increased use of propranolol, studies have also focused on relapses following propranolol therapy. Our current study evaluates the role of bleomycin triamcinolone...

Hemangioma Genetics and Associated Syndromes.
https://doi.org/10.1016/j.det.2022.07.001
Dermatologic Clinics; Luu J, Cotton CH

Oct 16th, 2022 - This article explores what is known regarding infantile hemangioma (IH) genetics. Despite a great deal of research on this topic, the relationship between IH genetics and pathogenesis has yet to be understood. This article also outlines the approp...

Apelin Receptor Can Act as a Specific Marker and Promising Therapeutic Target for Infan...
https://doi.org/10.1016/j.jid.2022.09.657
The Journal of Investigative Dermatology; Chen Q, Ying H et. al.

Oct 16th, 2022 - Infantile hemangioma (IH), the most common benign tumor in infancy, is generally sensitive to propranolol treatment. However, the challenge remains because resistance or recurrence could occur in some patients, and the mechanism or target of propr...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  24 results

Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
https://clinicaltrials.gov/ct2/show/NCT02342275

Jun 16th, 2022 - Currently, propranolol is the preferred treatment for problematic proliferating infantile hemangiomas (IHs). Although propranolol is clearly efficacious, rare side effects, such as hypoglycemia, may be life-threatening. The possibility of proprano...

Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
https://clinicaltrials.gov/ct2/show/NCT04113187

Jun 14th, 2022 - Hereditary Hemorrhagic Telangiectasia (HHT) is a rare systemic autosomal dominantly inherited disorder of angiogenesis. Its major feature is the occurrence in 90% of patients of spontaneous and recurrent epistaxis responsible for iron deficiency a...

Role of Propranolol as Compared to Bleomycin in Management of Hemangioma
https://clinicaltrials.gov/ct2/show/NCT05327309

Apr 14th, 2022 - Material & Methods Study design: Randomised controlled trial Place of study: This is study was conducted in the department of paediatric surgery, children hospital, Pakistan institute of medical sciences, Islamabad Duration of study: 24 months Num...

Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)
https://clinicaltrials.gov/ct2/show/NCT02913612

Jan 24th, 2022 - Primary: Describe the efficacy of 0.25% and 0.5% topical timolol maleate Gel-forming solution (GFS) as assessed through Infantile Hemangioma (IH) changes in volume. Secondary: Describe the safety of topical timolol maleate GFS for treatment of IH.

Clinical Characteristics of Infantile Hemangioma
https://clinicaltrials.gov/ct2/show/NCT03331744

Jan 4th, 2022 - Infantile hemangioma (IH) is the most common benign tumor of infancy with an estimated prevalence of 4%-5%. IHs may be presented in any part of body including the visceral organs, but are preferentially located on the face, head and neck area. IHs...

see more →

News  56 results

Nonselective Beta-Blockers May Improve Outcomes in Ovarian Cancer
https://www.medpagetoday.com/hematologyoncology/ovariancancer/100455

Aug 29th, 2022 - Women with cardiovascular conditions (CVCs) and ovarian cancer had better 2-year survival if they received a nonselective beta blocker (NSBB) at or around the time of cancer surgery, a review of medical records showed. Two-year postoperative survi...

Unique Dermatology Residency Track Focuses on Rural Placement of Graduates
https://www.medscape.com/viewarticle/973788

May 11th, 2022 - BOSTON – As a former active-duty cavalry officer in the U.S. Army who served a 15-month tour in Iraq in 2003, Adam C. Byrd, MD, isn't easily rattled. On any given day, as the only dermatologist in his hometown of Louisville, Miss., which has a pop...

Study Finds Nadolol Noninferior to Propranolol for Infantile Hemangiomas
https://www.medscape.com/viewarticle/963664

Nov 25th, 2021 - Pediatric dermatologists who treat infantile hemangioma (IH) can consider nadolol as a noninferior — and possibly a better — alternative to the standard treatment propranolol, according to a study published in JAMA Pediatrics. "In our experience, ...

Nadolol bests propranolol for infantile hemangioma treatment out to 52 weeks
https://www.mdedge.com/dermatology/article/242778/pediatrics/nadolol-bests-propranolol-infantile-hemangioma-treatment-out
Doug Brunk

Jul 12th, 2021 - Compared with oral propranolol for the treatment of infantile hemangiomas, oral nadolol resulted in faster and greater size involution and color resolution with a similar safety profile out to 52 weeks, results from a prospective analysis of 71 pa.

see more →

Patient Education  7 results see all →